Indication
TTR-mediated Amyloidosis
5 clinical trials
4 products
Clinical trial
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)Status: Completed, Estimated PCD: 2017-08-01
Product
PatisiranProduct
Sterile Normal SalineProduct
ALN-TTR02Clinical trial
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02Status: Completed, Estimated PCD: 2016-07-01
Clinical trial
A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR AmyloidosisStatus: Completed, Estimated PCD: 2013-10-01
Clinical trial
A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac AmyloidosisStatus: Completed, Estimated PCD: 2014-10-01
Product
ALN-TTRSC